RESEARCH STUDY AGREEMENT

This  Agreement  (the  "Agreement")  is  dated as of September 24, 2001, by and
between AngioGenex, Inc., a New York corporation  having  an  office at 825 3rd
Avenue,  New  York, New York 10021 (the "Company"), and Biocheck  (the  "CRO"),
located at 837 Cowan Road, Burlingame, CA.

                              W I T N E S S E T H
                              -------------------

WHEREAS, CRO has  the scientific personnel and facilities to conduct a research
program relating to the measurements of proteins in biological samples;

WHEREAS, Company desires  to  fund a research program at the CRO to investigate
the potential for measurements  of  Id  proteins in biological fluids to detect
the presence of cancer in the subjects providing the sample of the fluid;

WHEREAS, Sinfu Tzeng, Ph.D., President of Biocheck ("Dr. Tzeng"), is interested
in participating in and overseeing such a  research  program to be conducted at
the CRO;

WHEREAS, CRO is willing to allow Dr. Tzeng to participate in and oversee such a
research program pursuant to the terms of this Agreement;

NOW,  THEREFORE, Company and CRO (each sometimes referred  to  individually  as
"Party" or collectively as "Parties") hereto agree as follows:

1. SCOPE OF RESEARCH
   -----------------

1.1.CRO Obligations.  CRO agrees to undertake and use all reasonable efforts to
    ----------------
conduct certain specified  research  for  Company  (the "Study"). The scope and
operating  budget  for  the Study is set forth in Exhibit A  attached  to  this
Agreement.

1.2. Company Obligations.  Company  agrees  to undertake and use all reasonable
     --------------------
efforts to supply CRO with sufficient information  and materials in a form that
will  allow CRO to perform the Study. Supply of information  and  materials  by
Company  to  CRO  will  be  governed  by  the  terms of this Agreement and of a
material transfer agreement in substantially the  form of Exhibit B attached to
this Agreement (the "Material Transfer Agreement").  CRO understands and agrees
that materials supplied under the Material Transfer Agreement  are experimental
in nature, are not for use in humans, and are provided As-Is.

2. COMPENSATION
   ------------

2.1. Study Budget. For CRO's services hereunder, including, without limitation,
     -------------
use of CRO's laboratories, facilities, equipment and personnel,  including  the
portion of Dr. Tzeng's time required to oversee the Study, Company will pay CRO
according to the operating budget set forth in Exhibit A.

2.2. Schedule of Payments. Company will pay all compensation for work under the
     ---------------------
Study  directly  to  CRO. The Parties anticipate that work under the Study will
begin on or about October  1,  2001,  and end 30 days later. The date such work
under  the  Study actually begins is hereinafter  referred  to  as  the  "Study
Initiation Date."  Payment  for  work  under  the  Study  will  be  made  in  2
installments,  beginning  on the Study Initiation Date, as described in Exhibit
A. The Company shall have no obligation to make any other payments to CRO.

3. INVENTIONS
   ----------

3.1. Definition; Prompt Disclosure.  CRO  shall  disclose  to Company promptly,
     ------------------------------
fully and completely, together with all data and information  relating thereto,
all inventions, improvements, modifications, discoveries, products,  compounds,
compositions  of  matter,  apparatus,  methods,  formulae,  processes, computer
software  programs,  databases  and  trade secrets, whether or not  patentable,
copyrightable or protectible as trade  secrets,  that  are made or conceived or
first actually reduced to practice by CRO personnel, either  alone  or  jointly
with others, in the performance of the Study (the "Inventions").

3.2.   Ownership of Inventions.   All   Inventions   and  any  patents,  patent
       ------------------------
applications, copyrights and trade secrets relating thereto,  conceived  and/or
first actually reduced to practice in the performance of the Study are the sole
and  exclusive  property  of  Company, and CRO hereby assigns any rights it may
have in such to the Company.

3.3. Patent Protection. Company,  at  its  own  expense, may file and prosecute
     ------------------
applications for patents covering such Inventions as Company deems appropriate.

3.4.  Reasonable Assistance.  CRO  agrees  to  give  Company   all   reasonable
      ----------------------
assistance  requested  by  Company  in preparing, prosecuting, maintaining  and
defending any patent, copyright, trademark  or  other  statutory protection for
Inventions,  at  Company's  expense.  CRO agrees to cause to  be  executed  all
assignments  and  other  instruments  and  documents  that  Company  reasonably
considers necessary or appropriate to carry out the intent of this Agreement.

4. CONFIDENTIALITY
   ---------------

4.1 Obligation of Confidentiality.
    ------------------------------

a.  CRO  acknowledges  that  as a result of this  Agreement,  CRO  may  acquire
information, materials and knowledge  about  Company or its activities that are
confidential and proprietary (the "Proprietary Information").  CRO  agrees,  on
behalf  of  itself  and  its  personnel,  to  hold  in  confidence  Proprietary
Information  which  is  identified  as such in writing (or, if provided orally,
where notice of the confidentiality of  such information is provided in writing
within thirty (30) days), and not to directly  or  indirectly disclose, publish
or use, for the benefit of itself or any third party,  except  in  carrying out
the  Study  or  as  otherwise  expressly  permitted in writing, any Proprietary
Information  without  first  having  obtained prior  written  consent  to  such
disclosure or use.

b.  For  purposes of this Agreement, "Proprietary  Information"  is  deemed  to
include, but  is  not  limited to, information about the business of Company or
the business of any parent,  subsidiary,  affiliate,  customer  or  supplier of
Company or any other party with whom Company agrees to hold the information  of
such  party  in  confidence,  including  but  not  limited to Inventions, trade
secrets,  research  and  development  plans,  marketing plans,  product  plans,
business  strategies, financial information, forecasts,  personnel  information
and customer lists.

c. This obligation  of  nonuse and nondisclosure will not extend to Proprietary
Information:

(i) Which can be demonstrated  to  have been within CRO's legitimate possession
prior to the time of disclosure by Company to CRO;

(ii) Which was in the public domain  prior  to disclosure by Company to CRO, as
evidenced by documents which were generally published prior to such disclosure;

(iii) Which, after disclosure by Company to CRO,  comes  into the public domain
through no fault of CRO; or

(iv)  Which  is disclosed to CRO by a third party having legitimate  possession
thereof and the unrestricted right to make such disclosure.

4.1 Confidentiality Agreements for Employees and Consultants.   CRO  shall
    ---------------------------------------------------------
   obtain from  each of its employees, and any consultant(s) retained by CRO in
   the course of  performing  the  Study,  a  written agreement obligating such
   person  to comply with the provisions of this  Section  4  as  well  as  the
   disclosure  provisions  of  Section  3. CRO agrees to provide copies of such
   agreements to Company on request.

4.3 Obligations of Third Parties. Even if Company consents to the disclosure of
    -----------------------------
Proprietary Information to a third person pursuant to Section 4.1.a., CRO shall
obtain from each such person, prior to disclosure,  a written agreement placing
on  such  person  a corresponding obligation of confidentiality  regarding  the
Proprietary Information  disclosed,  on  substantially the same terms set forth
herein.

4.4.  Return of Materials.  If  Company  so  requests,  on  the  expiration  or
      --------------------
termination  of  this  Agreement,  CRO shall promptly  return  any  Proprietary
Information,   materials  and  other  property,   including   all   copies   or
reproductions thereof, delivered to CRO and relating to the Study.

5. REPORTS, ACCESS AND PUBLICATION
   -------------------------------

5.1. Reports.
     --------

a. Final Report.  Within  thirty  (30)  days  after  the  end  of  the Study or
termination of this Agreement, CRO will provide Company with a report detailing
the full results of the work conducted by Dr. Tzeng and/or her associates under
the Study.

5.2.  Access. CRO agrees that Company will have access, at any reasonable  time
      -------
during  and  after the expiration or termination of this Agreement, to all data
and results of  CRO's  work  concerning  the Study conducted during the term of
this Agreement. In addition, Company representatives  will be entitled to visit
CRO  from time to time on a reasonable basis to observe  the  progress  of  the
Study and discuss the same with Dr. Tzeng and other representatives of CRO.

5.3. Publication and Dissemination.
     ------------------------------

CRO may  not  publish  and disseminate information relating to various findings
made during the Study.

6. TERM AND TERMINATION
   --------------------

6.1 Term. This Agreement  will  become effective on the date first stated above
    -----
and will continue in effect for two (2) years from the Study Initiation Date.

6.2 Renewal. The Parties may renew the Agreement on the same nonfinancial terms
    --------
and conditions set forth herein,  with  the  written consent of each Party. The
budget for any additional term(s) shall be negotiated  in  good  faith  by  the
Parties.

6.3 Termination.  Either  Party may terminate the Agreement on sixty (60) days
    ------------
written notice.

6.4 Termination on Breach. Either  Party  may  terminate  the  Agreement in the
    ----------------------
event  of  a  material  breach  of  the Agreement by the other Party,  if  such
material breach has not been cured (if  such  is capable of cure) within thirty
(30) days after written notice.

6.5  Payment on Termination.  In  the  event  of  early   termination  of  this
     -----------------------
Agreement, CRO will stop incurring costs pursuant to the Study, effective as of
the date of termination. Final payment by Company will be prorated  so that the
total payment to CRO upon early termination will be equal to the total  payment
to CRO for the full term of work under the Study pursuant to this Agreement, as
set forth in Exhibit A, multiplied by a fraction, the numerator of which is the
number  of  days between the Study Initiation Date and the date of termination,
and the denominator  of  which  is  30  days,  except  that  should  CRO  incur
obligations  which  cannot  be  prorated,  CRO  shall  be  entitled  to receive
reimbursement  for such non-proratable obligation(s) in the final payment.  CRO
will not incur more  than  an aggregate of $5,000 in non-proratable obligations
without the prior written consent of Company.

6.6. No Waiver. Termination  of  this  Agreement  for  any  reason  will not be
     ----------
construed  as  a  waiver  by any Party of any of its rights, claims, (including
claims  for  damages)  or  obligations,  including  obligations  of  disclosure
pursuant to Section 3 and nondisclosure  and nonuse pursuant to Section 4, that
have accrued up to and including the date of termination.

7. USE OF NAME, TRADEMARK OR TRADE NAME.
   -------------------------------------

Neither Party will have the right to use the  name,  trademark or trade name of
the other, directly or indirectly, in conjunction with  any  product, promotion
or  publication,  without  the  prior  written  approval  of  the other  Party.
Notwithstanding the foregoing, Company shall have the right to  use  the  name,
trademark  or  trade  name  of CRO without the prior written approval of CRO in
connection with any filing by  the Company with the United States Food and Drug
Administration or United States Securities and Exchange Commission or any other
agency  with similar authority in  another  jurisdiction,  in  connection  with
disclosures made to potential investors or as required by law.

8. MISCELLANEOUS
   -------------

8.1 Amendment and Waiver. No waiver or modification of any of the terms of this
    ---------------------
Agreement  will be effective unless in a writing duly executed by both Parties.
No waiver by  either  Party  of a breach of any covenant of this Agreement or a
default hereunder will be deemed  a waiver by such Party of a subsequent breach
or default of like or similar nature.

8.2 Assignment. This Agreement will be binding upon and inure to the benefit of
    -----------
the Parties hereto, and their successors,  heirs  and  assigns. Other than in a
transaction or series of related transactions involving the merger, acquisition
or sale of all or substantially all of the assets or stock  of Company, Company
will  not  have  the right to assign this Agreement without the  prior  written
consent of CRO, which  will not be unreasonably withheld. CRO will not have the
right to assign this Agreement  without  the  prior written consent of Company,
which will not be unreasonably withheld.

8.3 Severability. If any provision of this Agreement  is  held unenforceable or
    -------------
in conflict with applicable law, then such provision will be excluded from this
Agreement.  The  balance  of  the  Agreement  will be interpreted  as  if  such
provision were so excluded and will be enforceable according to its terms.

8.4 Force Majeure. The Parties will not be liable  for  failure  or  delays  in
    --------------
performance  hereunder  due  to  fire, explosion, breakdown of plants, lockout,
labor disputes, casualty or accident,  lack  or  failure of source of supply of
labor,  raw  materials, power or supplies, acts of God  or  the  public  enemy,
interference by  civil  or  military  authorities or any other cause beyond the
reasonable control of the Party in question.

8.5 Notices. Unless otherwise provided,  any notice required or permitted to be
    --------
given  to a Party pursuant to the provisions  of  this  Agreement  will  be  in
writing  and will be effective and deemed effectively given to such Party under
this Agreement  on  the  earliest  of  the  following: (a) the date of personal
delivery;  (b)  one  (1)  business  day  after  transmission  by  facsimile  or
telecopier, addressed to the other Party at its facsimile  number or telecopier
address,  with  confirmation  of transmission; or (c) three (3)  business  days
after deposit with an express courier for international deliveries. All notices
not delivered personally or by  facsimile  will  be sent with fees and/or other
charges prepaid. All notices will be properly addressed  to  the  Party  to  be
notified  at  the address set forth below or at such other address as the Party
may designate by ten (10) days advance written notice to the other Party.

Biocheck:              John Chen, Chairman and CEO
                       Biocheck
                       837 Cowan Road
                       Burlingame, CA
                       FAX:  650.259.8427

AngioGenex:            W. A. Garland, COO
                       AngioGenex, Inc.
                       825 3rd Avenue
                       New York, New York 100484
                       FAX: 212.874.5027

With Copy to:          George Gould
                       Gibbons, Del Deo, Dolan, Griffinger & Vecchione
                       One Riverfront Plaza
                       Newark N.J. 07102-5487
                       FAX: 973.639.6460

8.6 Entire Agreement.  This  Agreement,  together with all the Exhibits hereto,
    -----------------
constitutes  and contains the entire understanding  between  the  Parties  with
respect  to  the   subject   matter   hereof   and   supersedes   all  previous
communications, representations, understandings and agreements, either  oral or
written,  between  the  Parties  or any official or representative thereof with
respect to the subject matter of this  Agreement.  It  is  expressly understood
that  no  other  inducements,  either oral or written, have been  made  to  the
Parties to enter into this Agreement other than the terms hereof.

8.7. Independent Contractors. For  purposes  of this Agreement and all services
     ------------------------
to  be  provided  hereunder,  the  Parties are, and  shall  be  deemed  to  be,
independent contractors and not agents  or  employees  of  the other Party. The
Parties  shall have no authority, and shall not give the appearance  of  having
any authority,  to  make  any statements, representations or commitments of any
kind, or to take any action  which  would be binding on the other Party, except
as may be expressly provided for or authorized in writing.

8.8. Dispute Resolution. Any and all  claims, disputes or controversies (except
     -------------------
for intellectual property issues) arising  under, out of, or in connection with
this Agreement, which have not been resolved by good faith negotiations between
the parties, will be resolved by final and binding  arbitration  in  San  Mateo
County, California under the rules of the American Arbitration Association then
in  effect.  The arbitration will be conducted by a single arbitrator, selected
in accordance  with  such  rules,  who  is knowledgeable in the general area of
pharmaceutical research and development and  in  the specific area of corporate
sponsored research projects. The arbitrator will render  a  written decision in
accordance with the governing law stating his or her reasons therefor, and will
render  an  award  within  three  (3)  months  of  the request for arbitration.
Judgment upon the award rendered by the arbitrator will be final and binding on
both parties and may be entered in any court of competent jurisdiction.

8.9 Injunctive Relief. The Parties recognize and agree that remedies at law for
    ------------------
breach  of  the  provisions  of  Sections  3 and 4 of this  Agreement  will  be
inadequate and that the non-breaching Party  shall,  in  addition  to any other
rights it may have, be entitled to injunctive relief.

8.10  Survival of Rights and Obligations.  The  rights and obligations  of  the
      -----------------------------------
Parties pursuant to Sections 3, 4, 5, 7 and 8 of  this  Agreement  will survive
and  continue  after  any expiration or termination of this Agreement and  will
bind the Parties and their legal representatives, successors and assigns.

8.11 Counterparts. This  Agreement  may  be  executed  in counterparts, each of
     -------------
which will be deemed an original, and all of which together will constitute one
and the same instrument.

8.12 Governing Law. This Agreement shall be governed by and construed under the
     --------------
internal laws of the State of California, USA. The Convention  on Contracts for
the International Sale of Goods shall not apply.

IN WITNESS WHEREOF, the Parties hereto have affixed their signatures  as of the
date written above.

BIOCHECK                                   ANGIOGENEX, INC.

____________________________               __________________________________
SIGNATURE                                  SIGNATURE
JOHN CHEN                                  W. A. GARLAND
CHAIRMAN AND CEO                           COO
DATE:                                      DATE:


List of Exhibits
----------------

Exhibit A: Work  Plan  Including  Budget  and Schedule of Payments for Research
Study

Exhibit B: Material Transfer Agreement



<PAGE>


                             EXHIBIT A. WORK PLAN


Antibodies  and  authentic standard of the Id  proteins  will  be  provided  by
AngioGenex.

Biocheck will design  an pilot assay appropriate to the specific properties and
characteristics of the  Id proteins, fortify plasma and serum with Id standards
and determine the limits  of  quantitation  of the pilot assay at an RSD (found
minus added/added) of 20% at the lower limits  and  5%  at  the  upper limit of
quantitation.

Biocheck   will   then   use   the  pilot  assay  described  above  to  analyze
representative control and cancer  patient  samples supplied by Angiogenex, and
report the results.

Study Budget: $20,000

Payment: A $15,000 payment will be made on initiation  of  the  study,  and the
remaining  amount  due  paid  on  receipt of a preliminary report to AngioGenex
presenting results of the study.


<PAGE>


                          MATERIAL TRANSFER AGREEMENT
                          ---------------------------



NAME AND ADDRESS OF RECIPIENT:
Dr. Sinfu Tzeng
President
Biocheck
837 Cowan Road
Burlingame, CA 94010

AngioGenex, Inc. ("AngioGenex") agrees  to provide Biocheck, Inc. ("Recipient")
with authentic Id proteins and antibodies to Id proteins (the "Material").  The
Material is proprietary material of AngioGenex,  and  is  provided to Recipient
solely under the following terms and conditions:

1. Material is provided solely for the purpose of noncommercial research use by
Recipient. Recipient agrees not to use Material for any other purpose.  Nothing
herein  shall be deemed to grant rights under any patent.  Material,  materials
made using  Material,  and/or  the results of experiments and data derived from
any use of Material will not be used by Recipient for any commercial product or
process or commercial product development effort in any way.

2.   Recipient  agrees  not to transfer  the  Material,  materials  made  using
Material, and/or the results  of  experiments  and data derived from any use of
Material to any other person or entity without the  prior written approval from
an officer of AngioGenex, and without such person or  entity  entering  into  a
Material  Transfer  Agreement with AngioGenex that contains terms substantially
similar to those in this Agreement.

3.  Recipient agrees  that the Material, materials made using Material, and the
results of experiments  and data derived from any use of Material including any
inventions derived using  the  Material will be and/or will remain the sole and
exclusive property of AngioGenex.  At the request of AngioGenex, Recipient will
return  all  remaining  Material  and  any  material  made  using  Material  to
AngioGenex.  Recipient shall provide  assistance,  and  execute  any  documents
required to file, maintain, prosecute or enforce any patent for such inventions
and assign all rights therein to AngioGenex, at the expense of AngioGenex.

4.   Recipient  agrees  to  keep  AngioGenex  informed  of all uses made of the
Material and any material, results of experiments and data  derived there from.
A summary of results of experiments and data generated utilizing  the  Material
will be provided to AngioGenex in writing at their conclusion.

5.   All  aspects  of  the  Material and information and materials derived from
Material are considered to be  Confidential by AngioGenex. For a period of five
(5) years from the date of this  Agreement,  Recipient will keep all results of
work  with  the  Material  involving  confidential   aspects,   and  any  other
confidential information related to the Material made available to Recipient by
AngioGenex (hereinafter collectively referred to as "Information"),  in  strict
confidence.   Information  shall  not  be  disclosed to any third party without
prior written permission from AngioGenex.

The above notwithstanding, Recipient's obligation of confidence with respect to
Information shall not extend to:

(a)  Information which Recipient can demonstrate  by  written records was known
to Recipient prior to disclosure by AngioGenex, provided  such  information was
not  obtained  by Recipient through disclosure by a third party receiving  such
information in confidence from AngioGenex; or

(b)  Information  which  is now public knowledge or becomes public knowledge in
the future other than by breach of this Agreement; or

(c)  Information which is  disclosed  to Recipient after the date of disclosure
by  AngioGenex by a third party who has  the  right  to  make  such  disclosure
without  violating  the  terms  of  this  Agreement  or  any other agreement of
confidence or secrecy with AngioGenex.

6.   Recipient understands and agrees that Material is experimental  in  nature
and that  it is provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY
PURPOSE AND  WITHOUT  ANY  OTHER  WARRANTY, EXPRESS OR IMPLIED, AND WITHOUT ANY
REPRESENTATION OR WARRANTY THAT THE  USE  OF THE MATERIAL WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHT OF ANY OTHER PARTY.

7.  Recipient agrees that in no event shall AngioGenex be liable for any use of
Material  by  Recipient  and that Recipient will  defend,  indemnify  and  hold
AngioGenex, its officers,  directors,  employees  and  agents harmless from any
loss,  claim,  damage  or  liability  of any kind which may arise  from  or  be
connected with any use, handling or storage of the Material.

8.   Recipient  agrees  to  comply with all  Government  guidelines  which  are
applicable to the Material, including biosafety procedures.

9.  This Agreement is not assignable, whether by operation of law or otherwise,
without the prior written consent of an officer of AngioGenex.

10.  Recipient agrees not to submit to a publisher or in any other way disclose
or  publish the results of any  experiment  or  other  use  of  Material  which
involves  confidential  aspects  without  the  written consent of an officer of
AngioGenex, and to acknowledge the contribution  of  AngioGenex  scientists, if
appropriate.  Such consent will not be unreasonably withheld.

11.   Recipient  recognizes and agrees that remedies at law for breach  of  the
provisions  of  this  agreement  by  Recipient  will  be  inadequate  and  that
AngioGenex shall,  in  addition  to  any  other  rights  which  it may have, be
entitled to injunctive relief.

12.   By  receipt  of  Material  and/or  execution of this Agreement, Recipient
acknowledges that Material is proprietary  material  of  AngioGenex and accepts
all of the terms and conditions of this agreement.

If  the foregoing terms and conditions are acceptable, please  so  indicate  by
signing  in  the space provided below and returning on fully signed copy of the
Agreement to AngioGenex, retaining the other copy for your records.

BIOCHECK, INC                              ANGIOGENEX, INC.


_________________________                  __________________________
SIGNATURE                                  SIGNATURE

John Chen                                  W. A. Garland
Chairman and CEO                           Chief Operating Officer

DATE:                                      DATE:


<PAGE>